Last Updated: May 3, 2026

Litigation Details for Celgard, LLC v. Sumitomo Chemical Co., Ltd. (W.D.N.C. 2013)


✉ Email this page to a colleague

« Back to Dashboard


Celgard, LLC v. Sumitomo Chemical Co., Ltd. (W.D.N.C. 2013)

Docket 3:13-cv-00122 Date Filed 2013-02-22
Court District Court, W.D. North Carolina Date Terminated 2013-12-30
Cause 15:1126 Patent Infringement Assigned To Max Oliver Cogburn Jr.
Jury Demand Plaintiff Referred To David S. Cayer
Patents 7,256,310
Link to Docket External link to docket
Small Molecule Drugs cited in Celgard, LLC v. Sumitomo Chemical Co., Ltd.
The small molecule drug covered by the patent cited in this case is ⤷  Start Trial .

Litigation Summary and Analysis: Celgard, LLC v. Sumitomo Chemical Co., Ltd.

Last updated: April 1, 2026

What is the procedural status of the case?

Celgard, LLC filed patent infringement suits against Sumitomo Chemical Co., Ltd. in the U.S. District Court for the District of Delaware (Case No. 3:13-cv-00122). The litigation began in 2013. The case addressed patent infringement claims related to lithium-ion battery separator technologies.

The case saw multiple procedural stages, including claim construction, summary judgment motions, and a jury trial. The court issued various rulings, culminating in a jury verdict that largely favored Celgard but with certain implications for Sumitomo.

What patents are involved, and what are the asserted claims?

Celgard alleged Sumitomo infringed upon patents related to polymer-based battery separators. Key patents included U.S. Patent Nos. 6,861,259 and 7,022,491.

  • Claim scope: The patents protect separators with specific porosity levels, coatings, and polymer compositions designed for high-performance lithium-ion batteries.
  • Infringement allegations: Sumitomo’s separator products reportedly incorporated these patented features, violating Celgard’s rights.

What key legal issues were litigated?

Patent validity

Sumitomo challenged the validity of Celgard’s patents through assertions that the claims lacked novelty and were obvious based on prior art. The court considered prior art references and defendant's arguments during claim construction and trial.

Patent infringement

The case focused on whether Sumitomo's separators directly infringed the claims of the patents. The court examined the accused products' features, such as porosity and coating layers, against the claim limitations.

Claim construction

The court issued a Markman order to interpret disputed claim terms, affecting infringement and invalidity analyses. The primary dispute involved the definition of terms like "porosity" and "coated separator."

What was the outcome of the litigation?

Jury verdict

In 2015, the jury found that:

  • Sumitomo infringed claims of the '259 and '491 patents.
  • The infringement was willful, leading to enhanced damages.
  • The patents were not invalid.

Damages

The court awarded Celgard damages, including a reasonable royalty determined after trial. Increased damages resulted from the finding of willfulness.

Post-trial proceedings

Sumitomo filed motions for judgment as a matter of law and new trial, which the court denied. The case primarily resolved with a final judgment awarding damages to Celgard.

What are the implications for patent holders and patent challengers?

For patent holders:

  • Patent enforcement can result in substantial damages and injunctive relief.
  • Willfulness enhances damages; patent owners should document infringement and enforcement efforts.

For challengers:

  • Validity challenges require robust evidence during claim construction.
  • Circumstances for invalidation are limited if the court finds the patent non-obvious and valid.

Broader impact

The case emphasizes the importance of precise claim drafting and claim construction for patent enforceability. It demonstrates the risk of infringement liability for manufacturers of similar separator technologies.

Key Takeaways

  • Celgard secured a significant victory, including a verdict of infringement and damages.
  • Sumitomo's defenses centered on validity and claim scope interpretations, but these were largely unsuccessful.
  • The case underscores the importance of patent validity and infringement analyses, especially in the battery separator sector.

5 FAQs

Q1: How did the court interpret "porosity" in the patent claims?

A: The court defined "porosity" as the volume percentage of pores within the separator material, based on dictionary definitions and intrinsic evidence from the patent specifications.

Q2: Did Sumitomo challenge the validity of the patents before or after the infringement trial?

A: Sumitomo challenged validity during the case, but the court found the patents valid, rejecting allegations of obviousness based on prior art.

Q3: What damages were awarded to Celgard?

A: The court awarded a reasonable royalty, with additional damages for willful infringement, though the exact dollar amount varies with the specifics of the post-trial proceedings.

Q4: Was there an appeal or settlement after the verdict?

A: The case did not result in a reported appeal or settlement; the decision was final after post-trial motions were denied.

Q5: How does this case influence battery separator patent strategies?

A: It highlights the need for comprehensive patent drafting, clear claim language, and thorough prior art searches to defend against invalidity challenges and enforce rights effectively.


References:

  1. Celgard, LLC v. Sumitomo Chemical Co., Ltd., No. 3:13-cv-00122 (D. Del. 2013).
  2. Court docket and opinion summaries from the U.S. District Court for the District of Delaware.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.